Preliminary unaudited cash, cash equivalents and marketable securities were approximately $820 million as of December 31, 2024. In the fourth quarter of 2024, the Company prepaid in full the loan outstanding under the Pharmakon Loan Agreement and also paid sales-related rebate accruals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore announces 2025 strategic priorities at JPM Conference
- Immunocore Holdings Strengthens Leadership with Key Appointment
- Immunocore appoints Travis Coy as CFO and Head of Corporate Development
- Immunocore announces first patient dosed in Phase 1 trial of IMC-P115C
- Immunocore announces treatment of first patient in Phase 1/2 trial of IMC-R117C